Despite Zhejiang Xinguang Pharmaceutical's recent poor growth, its P/E is similar to the market, indicating investor hopes for a business turnaround. However, unless medium-term conditions improve, current prices may not be sustainable. The recent earnings decline and market underperformance suggest a risk of further share price decline.